Innovent's PECONDLE® Phase 3 Study Clears Key Efficacy Endpoints for Psoriasis Treatment Success Innovent Biologics announces the successful completion of Phase 3 clinical trials for PECONDLE®, offering a promising long-term solution for psoriasis management by meeting all primary efficacy endpoints.

Innovent's PECONDLE® Phase 3 Study Clears Key Efficacy Endpoints for Psoriasis Treatment Success #China #Suzhou #Psoriasis #Innovent #PECONDLE

Innovent's PECONDLE® Becomes China's First Approved IL-23p19 Monoclonal Antibody Innovent's PECONDLE® (picankibart injection) is the first IL-23p19 monoclonal antibody approved in China for treating moderate-to-severe psoriasis.

Innovent's PECONDLE® Becomes China's First Approved IL-23p19 Monoclonal Antibody #China #Suzhou #Psoriasis #Innovent #PECONDLE